Within the dose range of 300–500 mg BID, the regulation of E2, progesterone, LH, and FSH by SHR7280 reached maximum inhibition and inhibition saturation, providing evidence of the recommended dose for further phase 2 study in patients with uterine fibroid related bleeding or endometriosis-associated pain. The gene discussed is BRD2; the disease is uterine corpus leiomyoma.